Role of adhesion molecules in cancer and targeted therapy

C Fan, F Xiong, S Zhang, Z Gong, Q Liao, G Li… - Science China Life …, 2024 - Springer
Adhesion molecules mediate cell-to-cell and cell-to-extracellular matrix interactions and
transmit mechanical and chemical signals among them. Various mechanisms deregulate …

[HTML][HTML] Nanomedicine Strategies for Targeting Tumor Stroma

MC Su, SK Nethi, PK Dhanyamraju, S Prabha - Cancers, 2023 - mdpi.com
Simple Summary The tumor microenvironment plays an important role in drug resistance
and supports/promotes tumorigenesis. Stromal modulators in combination with …

[HTML][HTML] Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival

D Hathi, C Chanswangphuwana, N Cho, F Fontana… - Scientific reports, 2022 - nature.com
Multiple myeloma (MM) is a cancer of bone marrow (BM) plasma cells, which is increasingly
treatable but still incurable. In 90% of MM patients, severe osteolysis results from …

[HTML][HTML] Unlocking drug resistance in multiple myeloma: adipocytes as modulators of treatment response

M Ochiai, S Fierstein, F XsSali, N DeVito, LR Purkey… - Cancers, 2023 - mdpi.com
Simple Summary Worldwide obesity has nearly tripled in the last fifty years. Obesity is a risk
factor for multiple myeloma, contributing to both an increased risk of multiple myeloma …

[HTML][HTML] Integrin α6β4 Confers Doxorubicin Resistance in Cancer Cells by Suppressing Caspase-3–Mediated Apoptosis: Involvement of N-Glycans on β4 Integrin …

Y Kariya, J Gu, Y Kariya - Biomolecules, 2023 - mdpi.com
Drug resistance is a major obstacle to successful cancer treatment. Therefore, it is essential
to understand the molecular mechanisms underlying drug resistance to develop successful …

[HTML][HTML] Mechanisms of cell adhesion molecules in endocrine-related cancers: a concise outlook

Y Ruan, L Chen, D Xie, T Luo, Y Xu, T Ye… - Frontiers in …, 2022 - frontiersin.org
Chemotherapy is a critical treatment for endocrine-related cancers; however,
chemoresistance and disease recurrence remain a challenge. The interplay between cancer …

[HTML][HTML] Targeting CAM-DR and mitochondrial transfer for the treatment of multiple myeloma

R Suzuki, D Ogiya, Y Ogawa, H Kawada, K Ando - Current Oncology, 2022 - mdpi.com
The prognosis of patients with multiple myeloma (MM) has improved dramatically with the
introduction of new therapeutic drugs, but the disease eventually becomes drug-resistant …

[HTML][HTML] Myeloma microenvironmental TIMP1 induces the invasive phenotype in fibroblasts to modulate disease progression

R Ishihara, T Oda, Y Murakami, I Matsumura… - International Journal of …, 2023 - mdpi.com
Tissue inhibitors of metalloproteinases (TIMPs) are endogenous matrix metalloproteinase
inhibitors. TIMP1 is produced by cancer cells and has pleiotropic activities. However, its role …

[HTML][HTML] Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high …

S Moriya, H Kazama, H Hino, N Takano, M Hiramoto… - Plos one, 2023 - journals.plos.org
We previously reported that macrolide antibiotics, such as clarithromycin (CAM), blocked
autophagy flux, and simultaneous proteasome and autophagy inhibition by bortezomib …

[HTML][HTML] S100A8 is a prognostic signature and associated with immune response in diffuse large B-cell lymphoma

Q Lin, J Su, Y Fang, Z Zhong, J Chen… - Frontiers in Oncology, 2024 - frontiersin.org
Background S100A8, a calcium-binding protein belonging to the S100 family, is involved in
immune responses and multiple tumor pathogens. Diffuse large B-cell lymphoma (DLBCL) …